Pipeline
SMSbiotech’s multiple therapeutic indication pipeline
SMSbiotech’s therapeutic pipeline spans multiple indications in respiratory, orthopedic, veterinary, and cosmeceutical applications. In respiratory care, programs targeting COPD and lung fibrosis are already in Phase I clinical trials. Current programs range from research and pre-clinical development to anticipated clinical submissions, with compassionate use pathways under consideration.
In addition to respiratory diseases such as COPD, Small Mobile Stem (SMS) cell therapy is being developed for chronic orthopedic conditions in both humans and animals (dogs and horses). Beyond these, SMSbiotech’s scientists and global research collaborators continue exploring new therapeutic applications to further expand the platform’s potential.
Indications
Compassionate
Use
Use
Research
Development
Pre-Clinical
Submission
Phase i/ii
Phase il/ili
Registration
Respiratory
COPD
Lung Fibrosis
Orthopedic
Joint Therapy (Human)
Disc Degeneration (Human)
Joint Therapy (Veterinarian)
Disc Degeneration (Veterinarian)
Cardiovascular Diseases
Microvascular Diseases
Other Indications
Different Indications
Cosmeceutical
Skin Anti-Aging
Scarring
SMSbiotech’s pipeline highlights ongoing development in respiratory, orthopedic, and cosmeceutical therapies.
